Risk‐Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2 ‐ ERG , PTEN , Ki‐67, and MRI ‐Derived Apparent Diffusion Coefficient Values
International Journal of Urology · 2026
DOI: 10.1111/iju.70346 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Nursinem Alkan Vurğun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pathology, Pamukkale University, Denizli, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, PTEN Phosphohydrolase, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Pamukkale University Scientific Research Projects Coordination Unit (BAP), Denizli, Turkey.
Abstract (Originalsprache)
Objective
To evaluate molecular, immunohistochemical, and radiological parameters associated with pathological upgrading in patients with ISUP Grade Group 1 (GG1) prostate cancer who underwent radical prostatectomy (RP).
Methods
A total of 106 patients diagnosed with ISUP GG1 prostate adenocarcinoma via needle biopsy and treated with RP between 2012 and 2022 were retrospectively analyzed. Based on final pathology, patients were categorized into No Upgrade, Low‐risk Upgrade, and High‐risk Upgrade groups. Biopsy specimens were evaluated for PTEN, ERG, and Ki‐67 expression and TMPRSS2‐ERG gene fusion status, while radiological parameters, including PI‐RADS v2.1 scores and ADC values (ADC tumor and ADC ratio ), were assessed based on preoperative multiparametric MRI.
Results
TMPRSS2‐ERG fusion positivity and elevated ERG expression were significantly more common in the High‐risk Upgrade group ( p < 0.01 and p = 0.04, respectively). PI‐RADS scores showed a stepwise increase, and ADC tumor values decreased across risk groups ( p = 0.01 and p = 0.03). No significant differences were observed for PTEN loss, Ki‐67 index, or ADC ratio .
Conclusion
Certain immunohistochemical, radiological, and molecular parameters may be predictive of pathological upgrading in GG1 prostate cancer. Incorporation of these biomarkers into diagnostic evaluation and treatment planning may aid in refining risk stratification and avoiding overtreatment in clinically indolent cases. Although ADC tumor values were significantly associated with upgrading, their correlation with molecular markers such as PTEN, ERG, Ki‐67, and TMPRSS2‐ERG fusion were not statistically significant. Trial Registration Project No: 2023TIPF001
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Pathology, Pamukkale University, Denizli, Turkey.
- Department of Radiology, Pamukkale University, Denizli, Turkey.
- Department of Urology, Pamukkale University, Denizli, Turkey.
ORCID-Profile: Nursinem Alkan Vurğun, Nilay Şen Türk, Sercan Vurğun, Ahmet Baki Yağcı, Sinan Çelen, Mesut Berkan Duran
Förderung
- Pamukkale University Scientific Research Projects Coordination Unit (BAP), Denizli, Turkey
Zitieren
APA
Alkan Vurğun, N., Şen Türk, N., Vurğun, S., Yağcı, A. B., Çelen, S., & Duran, M. B. (2026). Risk‐Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2 ‐ ERG , PTEN , Ki‐67, and MRI ‐Derived Apparent Diffusion Coefficient Values. International Journal of Urology. https://doi.org/10.1111/iju.70346
Vancouver
Alkan Vurğun N, Şen Türk N, Vurğun S, Yağcı AB, Çelen S, Duran MB. Risk‐Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2 ‐ ERG , PTEN , Ki‐67, and MRI ‐Derived Apparent Diffusion Coefficient Values. International Journal of Urology. 2026. doi:10.1111/iju.70346
BibTeX
@article{AlkanVurun2026,
author = {Alkan Vurğun, Nursinem and Şen Türk, Nilay and Vurğun, Sercan and Yağcı, Ahmet Baki and Çelen, Sinan and Duran, Mesut Berkan},
title = {Risk‐Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2 ‐ ERG , PTEN , Ki‐67, and MRI ‐Derived Apparent Diffusion Coefficient Values},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70346}
}
EUVIMED